Relay Therapeutics (RLAY) Income towards Parent Company (2019 - 2026)
Relay Therapeutics (RLAY) posted quarterly Income towards Parent Company of -$79.1 million for Q1 2026, down 1.49% year-over-year from -$80.3 million in Q1 2025, and down 125.53% quarter-over-quarter from -$35.1 million in Q4 2025.
Relay Therapeutics (RLAY) Income towards Parent Company (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported Income towards Parent Company for 8 consecutive years, with -$79.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income towards Parent Company fell 1.49% year-over-year to -$79.1 million; the TTM figure through Mar 2026 stood at -$262.4 million (up 64.77% YoY), while the FY2025 annual figure was -$756.2 million, up 1.75% from the prior year.
- Income towards Parent Company slipped to -$79.1 million in Q1 2026 per RLAY's latest filing, from -$35.1 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$35.1 million in Q4 2025 and bottomed at -$484.9 million in Q4 2024.
- Historically, Income towards Parent Company has averaged -$106.9 million across 5 years, with a median of -$82.7 million in 2024.
- Annual changes were most pronounced in 2024 — Income towards Parent Company tumbled 349.31% — and 2025, when it jumped 92.76%.
- Relay Therapeutics' Income towards Parent Company stood at -$75.1 million in 2022, then plunged by 43.77% to -$107.9 million in 2023, then tumbled by 349.31% to -$484.9 million in 2024, then surged by 92.76% to -$35.1 million in 2025, then sank by 125.53% to -$79.1 million in 2026.
- Business Quant data shows RLAY's Income towards Parent Company at -$79.1 million in Q1 2026, -$35.1 million in Q4 2025, and -$74.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -85.32 Mn |
| Mar 31, 2026 | -79.13 Mn |
| Dec 31, 2025 | -35.09 Mn |
| Sep 30, 2025 | -74.22 Mn |
| Jun 30, 2025 | -73.98 Mn |
| Mar 31, 2025 | -77.97 Mn |
| Dec 31, 2024 | -484.87 Mn |
| Sep 30, 2024 | -88.39 Mn |
| Jun 30, 2024 | -93.56 Mn |
| Mar 31, 2024 | -82.71 Mn |
| Dec 31, 2023 | -107.91 Mn |
| Sep 30, 2023 | -74.27 Mn |
| Jun 30, 2023 | -112.41 Mn |
| Mar 31, 2023 | -100.57 Mn |
| Dec 31, 2022 | -75.06 Mn |
| Sep 30, 2022 | -85.28 Mn |
| Jun 30, 2022 | -92.41 Mn |
| Mar 31, 2022 | -80.07 Mn |
| Dec 31, 2021 | -73.44 Mn |
| Sep 30, 2021 | -61.92 Mn |